Trial Profile
Efficacy and safety of everolimus to SAve REnal Function (SAREFU) in long term heart transplanted patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; ACE inhibitors; Ciclosporin
- Indications Heart transplant rejection
- Focus Adverse reactions
- Acronyms SAREFU
- 27 Apr 2013 Results at 5 years presented at the 33rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
- 14 Apr 2011 Three-year results presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
- 05 May 2010 Two-year primary endpoint results presented at the American Transplant Congress -- 10th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation (ATC)